NCT07543783 2026-04-22
Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by TACE-HAIC
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Not yet recruiting
Clinical Trials
26 trialsNCT03259035 2026-04-09
NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02359968 2026-03-18
PROTECT
Centre Oscar Lambret
Phase 2 Completed
NCT05702229 2026-03-18
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
AstraZeneca
Phase 2 Recruiting
NCT07323576 2026-02-09
INAVO-CRC
Hoffmann-La Roche
Phase 2 Withdrawn
NCT03092895 2026-01-29
A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Completed
NCT07353827 2026-01-20
FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT06106308 2026-01-12
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Cardiff Oncology
Phase 2 Active not recruiting
NCT06154538 2025-11-28
Immune Checkpoint Inhibitors + Chemotherapy Versus Chemotherapy in the Neoadjuvant Treatment of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT06529718 2025-11-17
SEVILLA
UNICANCER
Phase 2 Recruiting
NCT04656041 2025-11-14
Folfox+Irinotecan+Chemort In Esophageal Cancer
Massachusetts General Hospital
Phase 2 Recruiting
NCT04595266 2025-09-29
LIVERPEARL
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase 2 Active not recruiting
NCT07192185 2025-09-25
Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab
Sun Yat-sen University
Phase 2 Recruiting
NCT06253611 2025-09-22
BIG
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 2 Recruiting
NCT05024097 2025-08-27
PANTHER
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT07106034 2025-08-12
ONTOP
Shanghai Pudong Hospital
Phase 2 Not yet recruiting
NCT05480306 2025-08-03
DeFianCe
Leap Therapeutics, Inc.
Phase 2 Completed
NCT03186326 2025-06-29
SAMCO
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT03584711 2025-06-29
OPTIPRIME
Federation Francophone de Cancerologie Digestive
Phase 2 Completed
NCT05712356 2025-06-06
BOLSTER
Lisata Therapeutics, Inc.
Phase 2 Active not recruiting
NCT06991465 2025-05-28
Hypo-OPRA
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Recruiting
NCT05312398 2025-05-25
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
University of Campania Luigi Vanvitelli
Phase 2 Active not recruiting
NCT06907342 2025-05-25
COSENSE-1
St. Olavs Hospital
Phase 2 Recruiting
NCT06972498 2025-05-15
A Prospective Multicenter Study: Ivosimab + Chemotherapy as Neoadjuvant for Resectable pMMR/MSS CRC Liver Mets
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 2 Not yet recruiting
NCT06946849 2025-04-27
SED-RO-ICC
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting